Salivary Duct Carcinoma: Immunohistochemical Profile of an Aggressive Salivary Gland Tumour

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2003 Dec 3

PMID 14645349

Citations 28

Authors

A Etges

D S Pinto Jr

L P Kowalski

F A Soares

V C Araujo

Affiliations

Soon will be listed here.

Abstract

Background: Salivary duct carcinoma (SDC) is considered to be a distinct malignancy of the major salivary glands, because of its highly aggressive behaviour, and the high rate of recurrence, metastasis, and disease related death.

Aims: To investigate expression of the proteins involved in the retinoblastoma (pRb) and p53 pathways, which control cell cycle progression at the G1/S checkpoint, and also expression of the c-erbB-2 oncoprotein in SDCs.

Methods: Using a streptavidin-biotin method, five cases of SDC were evaluated immunohistochemically for the presence of cyclin D1, CDK4 (cyclin dependent kinase 4), p16 (CDK2A), pRb (retinoblastoma protein), E2F-1, p53, mdm2 (murine double minute 2), bcl-2, and the c-erbB-2 oncoprotein to determine whether there was a correlation between the expression of these proteins and patient outcome.

Results: All of the cases showed deregulation of the pRb and p53 pathways. Of the five patients analysed, only the patient with longterm survival (10 years) was not positive for c-erbB-2 expression.

Conclusions: c-erbB-2 overexpression was associated with a poor prognosis. Aggressive behaviour, recurrence, and metastatic potential do not appear to be related to cell cycle deregulation, but seem to be associated with the c-erbB-2 oncoprotein, which is involved in matrix degradation and proteolitic activity, in addition to increases in vessel permeability, endothelial cell growth, proliferation, migration, and differentiation. There was a correlation between c-erbB-2 oncoprotein expression and aggressive behaviour in SDCs.

Citing Articles

Frequency of and sex differences in cancer treatment-related cardiac dysfunction in trastuzumab-treated patients with salivary gland cancer: a retrospective cohort study.

Tamura Y, Tamura Y, Tada Y Cardiooncology. 2024; 10(1):44.

PMID: 39020443 PMC: 11253489. DOI: 10.1186/s40959-024-00248-8.

Evaluation of HER2/neu expression in different types of salivary gland tumors: a systematic review and meta-analysis.

Javaheripour A, Saatloo M, Vahed N, Gavgani L, Kouhsoltani M J Med Life. 2022; 15(5):595-600.

PMID: 35815077 PMC: 9262268. DOI: 10.25122/jml-2021-0394.

A case of carcinoma ex pleomorphic adenoma arising from multinodular pleomorphic adenoma of the buccal region.

Yamamoto K, Sato Y, Kondo Y, Tanaka H, Akiyama Y, Yamashita Y Clin Case Rep. 2019; 7(10):1994-1998.

PMID: 31624625 PMC: 6787811. DOI: 10.1002/ccr3.2417.

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma.

de Souza A, Altemani A, de Araujo N, Texeira L, de Araujo V, Soares A Clin Pathol. 2019; 12:2632010X19873384.

PMID: 31598607 PMC: 6764050. DOI: 10.1177/2632010X19873384.

The expression of PD-L1 in salivary gland carcinomas.

Vital D, Ikenberg K, Moch H, Rossle M, Huber G Sci Rep. 2019; 9(1):12724.

PMID: 31484986 PMC: 6726636. DOI: 10.1038/s41598-019-49215-9.

References

Lewis J, McKinney B, Weiland L, Ferreiro J, Olsen K . Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996; 77(2):223-30. DOI: 10.1002/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N. View

Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N . Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986; 319(6050):230-4. DOI: 10.1038/319230a0. View

Cho K, Lee S, Lee Y . Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck. 1999; 21(5):414-9. DOI: 10.1002/(sici)1097-0347(199908)21:5<414::aid-hed6>3.0.co;2-m. View

Lundberg A, Weinberg R . Control of the cell cycle and apoptosis. Eur J Cancer. 1999; 35(4):531-9. View

Nielsen G, Stemmer-Rachamimov A, Shaw J, Roy J, Koh J, Louis D . Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest. 1999; 79(9):1137-43. View

Felix A, El-Naggar A, Press M, Ordonez N, Fonseca I, Tucker S . Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996; 27(6):561-6. DOI: 10.1016/s0046-8177(96)90162-8. View

Kamio N . Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours. Virchows Arch. 1996; 428(2):75-83. DOI: 10.1007/BF00193934. View

Tan M, Yao J, Yu D . Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997; 57(6):1199-205. View

Kubbutat M, Jones S, Vousden K . Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630):299-303. DOI: 10.1038/387299a0. View

10.

Martinez-Barba E . Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg. 1998; 25(6):328-34. DOI: 10.1016/s1010-5182(97)80035-2. View

11.

Cerilli L, Swartzbaugh J, Saadut R, Marshall C, Rumpel C, Moskaluk C . Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. Hum Pathol. 1999; 30(10):1242-6. DOI: 10.1016/s0046-8177(99)90044-8. View

12.

Madrigal B, Garcia J, de Vicente J . Salivary duct carcinoma: an unusual case of long-term evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999; 88(5):597-602. DOI: 10.1016/s1079-2104(99)70092-2. View

13.

Schoelch M, Regezi J, Dekker N, Ng I, McMillan A, Ziober B . Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol. 2000; 35(3):333-42. DOI: 10.1016/s1368-8375(98)00098-0. View

14.

Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T . The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 2000; 5(12):4152-7. View

15.

Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett J, Obaya A . Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A. 2000; 97(5):2229-34. PMC: 15783. DOI: 10.1073/pnas.050586197. View

16.

Mineta H, Miura K, Takebayashi S, Ueda Y, Misawa K, Harada H . Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol. 2000; 36(2):194-8. DOI: 10.1016/s1368-8375(99)00078-0. View

17.

Bringold F, Serrano M . Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol. 2000; 35(3):317-29. DOI: 10.1016/s0531-5565(00)00083-8. View

18.

Eccles S . Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. Recent Results Cancer Res. 2000; 157:41-54. DOI: 10.1007/978-3-642-57151-0_5. View

19.

Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P . Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 2000; 36(4):334-9. DOI: 10.1016/s1368-8375(99)00093-7. View

20.

Shintani S, Mihara M, Nakahara Y, Kiyota A, Yoshihama Y, Ueyama Y . Infrequent alternations of RB pathway (Rb-p16INK4A-cyclinD1) in adenoid cystic carcinoma of salivary glands. Anticancer Res. 2000; 20(3B):2169-75. View